Breathe Life Sciences (BLS), a subsidiary of Bioxyne Limited, has secured its initial medicinal cannabis supply agreement for flower products in Costa Rica. This development expands the company’s presence in the Latin American market, building on an existing agreement for other product forms. The deal was struck with Remidose LATAM, a Costa Rican entity of the Canadian firm Remidose Aerosols, which specializes in precision-dosed metered THC inhalers and transdermal topical gels, as reported by Cannabiz.com.au.
Expansion of Medicinal Cannabis Supply into Costa Rica
The new agreement specifically covers the supply of three Dr Watson-branded cannabis flower stock-keeping units (SKUs). Bioxyne stated that this arrangement marks the first international supply of branded medicinal cannabis flower into Costa Rica, signifying a notable step in the country’s developing medical cannabis framework. The first shipment is anticipated before June 30, with the initial invoice projected to exceed $500,000, according to company statements.
This flower supply deal builds upon a prior agreement established in December 2025 between BLS and Remidose LATAM, which focused on the supply of pastilles into both Costa Rica and Panama. The rapid expansion of product scope, from pastilles to flower, within a relatively short period, indicates an evolving demand profile and increasing market maturity in the region for diversified medical cannabis products.
Strategic Market Positioning in Latin America
Sam Watson, Chief Executive of Bioxyne, commented on the accelerated progression of market opportunities. He noted that the company has moved from an initial agreement to a broader supply scope within a short timeframe, attributing this to the strength of the relationship with Remidose LATAM and observed demand in the market. Watson highlighted that the Latin American market is in its early stages of development, presenting a strategic opportunity for early entrants to establish market share and brand recognition.
The company’s strategy involves leveraging its initial foothold to expand further. Key aspects of this strategic positioning include:
- Being the first to supply branded medicinal cannabis flower into Costa Rica, which positions Bioxyne ahead of potential competing suppliers in a newly opening market.
- Establishing a platform for potential expansion into other Latin American jurisdictions as their respective medical cannabis markets continue to mature and open to international trade.
- Capitalizing on the opening of markets across the region, which are allowing for the import and distribution of medical cannabis products.
This move aligns with Bioxyne’s broader international expansion efforts, as previously reported by Hemp Gazette, demonstrating a consistent strategy of targeting emerging medical cannabis jurisdictions.
Market Demand and Commercial Outlook
Michael Mayne, Managing Director of Remidose, expressed satisfaction regarding the inaugural shipment of medicinal cannabis flower into Costa Rica, specifically with the Dr Watson-branded products. He indicated that early demand signals have been robust, suggesting that initial stock could be fully committed before the product even arrives in the market. This strong pre-market demand underscores the potential for significant growth in Costa Rica’s nascent medical cannabis sector and validates the commercial viability of the partnership.
The reported demand suggests a readiness among Costa Rican patients and prescribers for regulated, internationally sourced medical cannabis flower. For Bioxyne, this initial success in securing and fulfilling a substantial order for medicinal cannabis supply could serve as a model for future engagements in other Latin American countries. The financial implications of an initial invoice exceeding $500,000 also highlight the immediate revenue potential of such early-mover agreements in developing markets.
The collaboration between Bioxyne’s subsidiary and Remidose LATAM aims to address this demand and establish a significant presence in the region’s evolving regulatory landscape for medical cannabis, potentially influencing future policy and market development.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
